Document is current

Article History

Received: 24 July 2025

Accepted: 27 September 2025

First Online: 4 December 2025

Declarations

:

: This study is based on the analysis of de-identified patients in the IQVIA claims databases, and confidentiality of patient records was maintained at all times. Study results were in tabular form and aggregate analyses that omit subject identification. Any publications and reports will not include subject identifiers. A waiver of informed consent was not required for this study.

: Not applicable.

: Y.C. reports relationships with GSK, Medtronic, and Sanofi for advisory boards and speaker’s bureaus, and Stryker for speaker’s bureaus. M–N.C. reports relationships with Covis, GSK, Novartis, and Sanofi on advisory boards and speaker’s bureaus. J.B. and J.R. are employed by Asthma Canada which has received funding from AstraZeneca, GSK, Novartis, Pfizer, and Sanofi, and consulting fees from Roche. K.U. and D.T. are employed by, and hold financial equities in, GSK. A.Te., J.L., and H.Y. are employed by IQVIA, which received funding from GSK for this study. A.Th. reports relationships with AstraZeneca, GSK, and Sanofi on advisory boards and speaker’s bureaus in addition to consulting for Storz and Stryker.